ne 58051 has been researched along with paclitaxel in 1 studies
Studies (ne 58051) | Trials (ne 58051) | Recent Studies (post-2010) (ne 58051) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
---|---|---|---|---|---|
17 | 0 | 2 | 31,874 | 5,729 | 15,395 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
1 other study(ies) available for ne 58051 and paclitaxel
Article | Year |
---|---|
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |